SOURCE: OTSP

November 13, 2006 09:10 ET

Study to Be Published in JAMA: Diabetes Drug ACTOS® (pioglitazone HCl) Halted Progression of Key Marker for Atherosclerosis; Improvements Indicated by Carotid Intima-Media Thickness (CIMT)

The CHICAGO Trial -- (Carotid Intima-Media Thickness in Atherosclerosis Using Pioglitazone)

CHICAGO, IL -- (MARKET WIRE) -- November 13, 2006 -- Researchers today presented data showing that ACTOS® (pioglitazone HCl) halted the progression of atherosclerosis, as indicated by carotid intima-media thickness (CIMT), in patients with type 2 diabetes. Results from the clinical trial CHICAGO (Carotid intima-media tHICkness in Atherosclerosis using pioGlitazOne), were published in an early online issue of the Journal of the American Medical Association.

Atherosclerosis, a condition that leads to reduced or blocked blood flow, is accelerated in patients with type 2 diabetes. A thickened carotid-intima media layer, or CIMT, is a surrogate marker for heart attack and stroke. CIMT is defined as the thickness of the inner lining of a patient's carotid, or neck artery. Measuring CIMT using ultrasonography is a well-accepted, noninvasive way to assess atherosclerosis.

The CHICAGO study is the largest and longest study to examine the effects of ACTOS on CIMT in patients with type 2 diabetes. It was a 25-center, randomized, 18-month study that enrolled over 400 ethnically diverse subjects with type 2 diabetes all from the Chicago area. This study is unique because all of the patients were based in Chicago institutes, therefore reducing the amount of inconsistencies within laboratories and readings.

The Medical News footage will contain:

--  CHICAGO Trial Description
--  Trial Results & Design
--  Carotid Intima-Media Thickness Animation
--  Soundbites from CHICAGO trial investigator
--  About ACTOS® (pioglitazone HCl)
    

MONDAY, NOVEMBER 13, 2006

11:00AM - 11:15AM EASTERN
2:30PM - 2:45PM EASTERN


COORDINATES FOR BOTH FEEDS:
IA 5, TRANSPONDER C 13
97 DEGREES WEST DLF: 3960.000 V

Contact Information

  • For more information, please contact:
    Jim Bowling
    323-930-5830